LDM (Local Dynamic Micromassage) in Seoul | Non-Thermal Ultrasound

LDM (Local Dynamic Micromassage) at Delight Dermatology in Gangnam, performed under Dr. SangYoul Yun, Board-Certified Dermatologist (male). LDM uses a Wellcomet (Karlsruhe, Germany) handpiece that rapidly alternates between two or three ultrasound frequencies (3 MHz and 10 MHz for LDM-MED, or 1, 3, 10 MHz and 3, 10, 19 MHz on the LDM-Triple platform) to produce a non-thermal mechanical micromassage at the cellular scale. Honest framing — the device is CE-marked under EU MDR (Notified Body BSI 2797) and is NOT FDA-cleared (Wellcomet does not market the platform in the United States); Korean MFDS approval is inferred via the Wellcomet Asia Seoul subsidiary in operation since 2010 but operators should verify the medical device permit number at first appointment. Korean marketing names the device 수광 광선 ("Sugwang lightwave") or 독일 광선 ("German lightwave") — the "광선" (lightwave) terminology is technically incorrect because LDM is acoustic ultrasound, not light energy. We use LDM as an athermal comfort and recovery adjunct after laser, peel, or microneedling and as an in-office option for diffuse rosacea redness counseling, not as a standalone therapeutic primary. First-line rosacea management remains topical metronidazole, ivermectin, or azelaic acid plus brimonidine for transient erythema and PDL or IPL for persistent telangiectasia per Schaller 2020 ROSCO consensus.

1. Immediate (Day 0)

   Subjective in-session sensation: comfortable, warm-water-feeling, non-painful, no thermal heat. Post-session appearance: typically unchanged or mild transient flush only. Patient can apply make-up the same day, return to normal activity immediately, no downtime. Subjective patient-reported outcome: "glow" or "smoother feel" frequently reported but not objectively measured by published TEWL, barrier function, or erythema-index data.

2. 24-72 hours (transient window)

   Any transient flush resolves within hours. No visible inflammation. No flaking, crusting, or peeling. If paired with same-day or 24-72 hour prior laser, peel, or microneedling, the recovery profile is dominated by the paired procedure, not by LDM. No published RCT confirms accelerated recovery from these paired procedures with LDM adjunct — extrapolated from Ahn 2023 (PMID 37877460) post-rhinoseptoplasty edema reduction signal.

3. End of 4-6 weekly session course (subjective cumulative)

   Patient-reported subjective improvement in skin comfort, perceived hydration, or perceived "glow" frequently reported across 4-6 weekly sessions. No objective TEWL, transepidermal water loss, or barrier function improvement RCT exists to confirm these patient-reported outcomes. For rosacea diffuse erythema specifically: any subjective redness reduction reflects either regression-to-the-mean (rosacea fluctuates with trigger exposure) or genuine adjunct benefit on top of first-line topical metronidazole, ivermectin, or azelaic acid — but is not attributable to LDM in isolation because no rosacea LDM RCT exists.

4. Post-rhinoseptoplasty edema window (3-8 weeks)

   The strongest published clinical effect — Ahn 2023 (PMID 37877460) Korean RCT showed LDM accelerated edema reduction in post-rhinoseptoplasty patients vs sham control. This is the single PubMed-indexed independent LDM RCT and is the indication with the cleanest evidence base. The study includes a Wellcomet co-author disclosure which we disclose at consult.

5. Maintenance interval (3-6 months and beyond)

   No published evidence base for maintenance LDM beyond an acute course. We do NOT pre-sell open-ended 10-pack maintenance subscriptions without a clear clinical indication. Patients electing continuation typically self-pace at 1-2 sessions per month for comfort and subjective benefit; we counsel honestly that this is patient-preference territory, not RCT-grounded clinical recommendation.

6. Realistic outcome ceiling (honest framing)

   LDM is a comfort and recovery adjunct with sparse manufacturer-affiliated evidence. The realistic outcome ceiling is: subjective in-session comfort, possible post-rhinoseptoplasty edema reduction (single RCT), and modest patient-reported cumulative subjective improvement over a 4-6 weekly course. We will NOT use "miracle skin barrier recovery," "replaces topical rosacea medication," "FDA-approved," "TÜV-certified," "the German gold standard," "permanent," or "cure" language. If you are seeking dramatic objective improvement in rosacea redness, telangiectasia, scars, pigment, or anti-aging, LDM is not the right modality and we will route you to evidence-based first-line care.

7. No objective TEWL / barrier function RCT — explicit disclosure

   Manufacturer-narrative claims of LDM-induced TEWL improvement, barrier function recovery, and hyaluronidase suppression are NOT confirmed by independent PubMed-indexed RCT evidence. The hyaluronidase suppression claim in particular is a manufacturer hypothesis without PubMed confirmation. We do not present these mechanism claims as established — they are framed as manufacturer hypotheses to be confirmed by future independent research.

1. 01

   Consultation and diagnosis by Dr. SangYoul Yun (male, Board-Certified Dermatologist). 30-minute assessment includes rosacea subtype classification (erythematotelangiectatic, papulopustular, phymatous, ocular per the 2017 National Rosacea Society Expert Committee phenotype framework) for rosacea patients, baseline topical and oral regimen review (metronidazole, ivermectin, azelaic acid, brimonidine, oral doxycycline 40 mg modified-release), trigger profile (sun, heat, alcohol, spicy food, stress, topical irritants), and Fitzpatrick skin type. For non-rosacea patients seeking comfort or recovery adjunct: prior procedure history, sensitive-skin baseline, expectation calibration.

2. 02

   **Explicit evidence and regulatory disclosure** — Written disclosure in patient's preferred language documenting: (1) Wellcomet LDM is CE-marked under EU MDR Class IIa (Notified Body BSI 2797, Netherlands) — NOT FDA-cleared, and Wellcomet does not market the platform in the United States. (2) Korean MFDS approval is inferred via the Wellcomet Asia Seoul subsidiary since 2010 (Trade Tower, Gangnam-gu); operators verify the medical device permit number at first appointment. (3) The published evidence base is sparse — only Ahn 2023 (PMID 37877460) Korean RCT in post-rhinoseptoplasty edema is independent and PubMed-indexed; Chervinskaya cellulite and acne case series are Wellcomet-affiliated. (4) No PubMed-indexed RCT exists for rosacea, sensitive skin barrier, post-laser recovery, or post-microneedling LDM specifically — all such applications are evidence-extrapolations. (5) AAD, ASLMS, EADV, and KDA have not published an LDM-specific consensus paper. (6) Korean marketing 수광 광선 or 독일 광선 is technically incorrect — "광선" (lightwave) is misleading because LDM is acoustic ultrasound, not light.

3. 03

   **Honest rosacea framing for rosacea patients** — First-line rosacea management is established and is NOT LDM: topical metronidazole 0.75-1%, ivermectin 1% cream, or azelaic acid 15% gel for inflammatory lesions; topical brimonidine 0.33% gel for transient erythema; pulsed dye laser (PDL) or intense pulsed light (IPL) for persistent telangiectasia and background erythema; oral doxycycline 40 mg modified-release for papulopustular phenotype where indicated. Schaller 2020 ROSCO consensus (PMID 31919587) is the authoritative phenotype-based framework. LDM is positioned as a comfort and recovery adjunct only — patients refusing first-line topical pharmacotherapy or PDL/IPL for telangiectasia are routed back to first-line care before any LDM consideration.

4. 04

   **Cleansing and skin preparation** — Standard cleansing, no anesthesia required (LDM is athermal and non-painful), no topical numbing cream needed. Hair tied back, face neutralized to baseline. Photographic documentation at baseline (standardized lighting, three angles) for any rosacea or scar course where serial comparison is planned.

5. 05

   **Coupling gel application** — A water-based or glycerin-based ultrasound coupling gel is applied to the treatment zone. We use a hypoallergenic coupling gel and screen for propylene glycol sensitivity (the most common LDM-related allergic contact dermatitis trigger). Patients with documented propylene glycol allergy or prior coupling-gel reaction are offered a patch-tested alternative or excluded from LDM.

6. 06

   **LDM handpiece pass — 20 to 30 minutes** — The handpiece is moved across the treatment zone in smooth, overlapping circular motion. The device internally alternates between 3 MHz and 10 MHz (LDM-MED) or between 1, 3, 10 MHz and 3, 10, 19 MHz triplets (LDM-Triple) at a switching rate fast enough to produce a non-thermal mechanical micromassage at the cellular scale per Kruglikov manufacturer-narrative reviews and Hormozi Moghaddam 2025 (PMID 40110447) independent in-vitro fibroblast and Type I collagen evidence. Output power is conservative; no thermal sensation, no audible cavitation, no anesthesia required. Patient typically experiences this as a comfortable, warm-water-feeling sensation.

7. 07

   **Post-session cooling and review** — Cooling pack applied 5-10 minutes if requested for subjective comfort (not therapeutically necessary). Coupling gel removed with gentle cleansing. Skin appearance immediately post-session: typically unchanged with mild transient flush at the most. Patient leaves without bandage, without downtime, can apply make-up the same day. Realistic endpoint counsel: "comfort and subjective glow today, modest cumulative effect over 4-6 weekly sessions if you elect to continue, no objective TEWL or barrier function improvement RCT to cite."

8. 08

   **Follow-up and course planning** — If single-session comfort adjunct: no follow-up required. If 4-6 weekly course elected for cumulative effect: weekly intervals across 4-8 sessions, photo documentation at sessions 1, 4, and 8, honest counsel that any visible change is modest and patient-reported rather than objectively measured. We will NOT pre-sell a 10-pack maintenance package without a clear clinical indication, and we will NOT compress multiple LDM sessions into a single trip beyond what one weekly cadence permits.

1. 01Day 0 (first 24 hours)

   No specific LDM aftercare required — the modality is athermal and non-injurious. If LDM was a recovery adjunct paired with same-day or 24-72 hour prior laser, peel, or microneedling, follow the paired procedure's aftercare in full: bland emollient (Cetaphil, La Roche-Posay Toleriane, Avene Cicalfate, or equivalent) twice daily, strict mineral SPF 50+ broad-spectrum every 2-3 hours outdoors, no hot showers / sauna / jjimjilbang / hot yoga / vigorous exercise / alcohol for 24-48 hours per paired procedure. Make-up application same-day permitted after LDM-only sessions. Continue baseline rosacea topical pharmacotherapy (metronidazole, ivermectin, azelaic acid, brimonidine) without pause.

2. 02Day 1-7 (recovery and observation window)

   Continue baseline skincare. Continue baseline rosacea topical pharmacotherapy without pause. Monitor for any delayed reaction at the coupling-gel application zone — propylene glycol allergic contact dermatitis is the most common LDM-related adverse event and typically presents as well-demarcated erythematous plaque or pruritus 24-72 hours post-session. Report any new persistent redness, scaling, pruritus, or vesiculation to clinic via KakaoTalk / WhatsApp / LINE messenger for assessment and possible coupling-gel substitution at the next session.

3. 03Week 2-8 (course continuation)

   If electing the weekly 4-8 session course: maintain weekly cadence, photo documentation at sessions 1, 4, and 8 for serial comparison, honest endpoint check-in at session 4 ("are you experiencing the subjective comfort benefit you came here for?") with explicit option to discontinue without penalty if no benefit. For rosacea patients: confirm baseline topical pharmacotherapy adherence continues throughout the LDM course — LDM is an ADJUNCT, not a replacement, and discontinuing first-line topical care during the LDM course is a red flag for the clinical relationship.

4. 04Month 2-6 (post-course observation)

   For rosacea adjunct: continue baseline topical pharmacotherapy indefinitely. Any subjective redness reduction attributable to LDM is not durable beyond patient-reported in-the-moment comfort — there is no published evidence base for sustained rosacea improvement from LDM alone. For post-rhinoseptoplasty edema: edema reduction signal per Ahn 2023 (PMID 37877460) is documented through the surgical recovery window (typically 8-12 weeks post-rhinoseptoplasty); no LDM maintenance is indicated beyond surgical recovery completion.

5. 05Long-term maintenance (6 months and beyond)

   No published evidence base for long-term maintenance LDM beyond an acute course. We do NOT pre-sell open-ended 10-pack maintenance subscriptions without clear clinical indication. Patients electing continuation typically self-pace at 1-2 sessions per month for comfort and subjective benefit — we counsel this honestly as patient-preference territory, not RCT-grounded clinical recommendation. For rosacea: lifelong first-line topical pharmacotherapy (metronidazole, ivermectin, azelaic acid, brimonidine) plus trigger management is the chronic-disease standard; LDM does not replace this.

The clinical claims on this page — device specs, efficacy timelines, safety profile — are supported by the primary sources below. Each citation links to the original paper or regulatory record.

1. [1]LDM dual-frequency ultrasound accelerates post-rhinoseptoplasty edema reduction — Korean RCT (single independent LDM RCT in PubMed). Aesthetic Plast Surg (Ahn — Wellcomet co-author disclosure) (2023).
2. [2]LDM in-vitro fibroblast viability and Type I collagen induction — independent mechanistic evidence. Lasers Med Sci (Hormozi Moghaddam) (2025).
3. [3]ROSCO global rosacea consensus — phenotype-based treatment recommendations (first-line topical and laser). Br J Dermatol (Schaller — ROSCO Consensus) (2020).
4. [4]Updated ROSCO recommendations for the management of rosacea — phenotype-based algorithm. Br J Dermatol (Schaller — ROSCO Consensus) (2017).
5. [5]Standard classification and pathophysiology of rosacea — National Rosacea Society Expert Committee. J Am Acad Dermatol (Gallo NRS Expert Committee) (2018).
6. [6]Standard grading system for rosacea — National Rosacea Society Expert Committee phenotype framework. J Am Acad Dermatol (Tan NRS Expert Committee) (2018).
7. [7]Caveolin-1 (CAV1) mechanotransduction in skin — biological substrate for non-thermal mechanical ultrasound. Int J Biochem Cell Biol (Kruglikov) (2014).
8. [8]Non-thermal mechanical ultrasound effects on connective tissue — mechanistic review (manufacturer-affiliated narrative). J Cosmet Dermatol (Kruglikov) (2015).
9. [9]Pulsed dye laser for facial telangiectasia and rosacea erythema — evidence base for first-line vascular targeting. Lasers Surg Med (Tan) (2018).
10. [10]Intense pulsed light vs pulsed dye laser for rosacea — comparative review. Lasers Med Sci (Husein-ElAhmed) (2017).